Leading biopharma to unify global regulatory operations on a single platform
to speed submissions for new patient therapies<\/i><\/p>\n
BARCELONA, Spain \u2014 4 Feb 2025 \u2014 <\/strong>³Ô¹Ï±¬ÁÏ Systems<\/a> (NYSE: VEEV) today announced that Servier<\/a> will adopt ³Ô¹Ï±¬ÁÏ RIM<\/a> to unify its global regulatory operations. By bringing regulatory processes together on a single platform, Servier can improve visibility, submission speed, and compliance. <\/p>\n “Unifying regulatory data, documents, and processes on ³Ô¹Ï±¬ÁÏ RIM will help Servier streamline operations and accelerate patient access to new medicines,” said Alexandra Pearce, global head, worldwide regulatory affairs at Servier. \u201cWith ³Ô¹Ï±¬ÁÏ, we have a reliable partner to help us scale and connect teams while driving better regulatory oversight and reducing time to submission.\u201d <\/p>\n With headquarters in France, Servier is an independent, global pharmaceutical leader in delivering cardio-metabolism, venous diseases, and oncology therapies. ³Ô¹Ï±¬ÁÏ RIM is a unified platform of regulatory applications, including ³Ô¹Ï±¬ÁÏ Registrations<\/a>, ³Ô¹Ï±¬ÁÏ Submissions<\/a>, ³Ô¹Ï±¬ÁÏ Submissions Publishing<\/a>, and ³Ô¹Ï±¬ÁÏ Submissions Archive<\/a>, offering biopharmas like Servier real-time visibility throughout the regulatory process. With ³Ô¹Ï±¬ÁÏ RIM, Servier has a solution that enables quick adaptation to evolving EU regulatory demands. ³Ô¹Ï±¬ÁÏ is partnering with Servier to roll out the technology across Europe, and globally, streamlining regulatory operations to reduce time to market for new therapies. <\/p>\n \u201cServier is showing true digital leadership in its approach to transforming its regulatory operations,\u201d said Paul Attridge, vice president of ³Ô¹Ï±¬ÁÏ RIM strategy at ³Ô¹Ï±¬ÁÏ Europe. \u201cWith our successful\u202ftrack record implementing ³Ô¹Ï±¬ÁÏ RIM, ³Ô¹Ï±¬ÁÏ\u2019s French and global teams look forward to helping Servier advance its regulatory management and deliver medicines to patients more quickly.\u201d <\/p>\n ³Ô¹Ï±¬ÁÏ RIM is part of ³Ô¹Ï±¬ÁÏ Development Cloud<\/a>, the technology foundation for product development across clinical, regulatory, quality, and safety. <\/p>\n Additional Information<\/strong><\/p>\n For more on ³Ô¹Ï±¬ÁÏ RIM, visit: veeva.com\/eu\/³Ô¹Ï±¬ÁÏRIM<\/a> <\/p>\n Connect with ³Ô¹Ï±¬ÁÏ on LinkedIn: linkedin.com\/company\/veeva-systems<\/a> <\/p>\n <\/p>\n About ³Ô¹Ï±¬ÁÏ Systems<\/strong> <\/p>\n <\/strong><\/p>\n ³Ô¹Ï±¬ÁÏ is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 1,000 customers, ranging from the world\u2019s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation<\/a>, ³Ô¹Ï±¬ÁÏ is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com\/eu<\/a>. <\/p>\n ³Ô¹Ï±¬ÁÏ Forward-looking Statements<\/strong><\/p>\n This release contains forward-looking statements regarding ³Ô¹Ï±¬ÁÏ\u2019s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2024, which you can find\u202fhere<\/a>\u202f(a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at\u202fsec.gov<\/a>. <\/p>\n ### <\/p>\n <\/center><\/p>\n